Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab (SHR-1210) in Advanced Melanoma
NCT02738489Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2016
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab in melanoma (3 cohorts), sponsored by Hengrui. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs) and Number of Participants Experiencing Severe AEs (SAEs). Started Apr 2016; status: completed.
02
Drugs
camrelizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02738489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738489.